摘要
目的观察中医益气通络解毒疗法联合贝伐珠单抗治疗复发转移性直肠癌的临床疗效。方法选择上海中医药大学附属曙光医院2019年1月-2022年6月收治的80例复发转移性直肠癌患者,采用随机数表法分为靶向组与中医组,各40例。2组均给予FOLFIRI方案化疗,靶向组加用贝伐珠单抗进行靶向治疗,中医组在靶向组基础上联合中医益气通络解毒方治疗。统计2组客观有效率、临床获益率、毒性反应程度,比较2组中医症状评分、血管内皮细胞生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)、胰岛素样生长因子1(IGF-1)水平变化。结果中医组客观有效率(55.00%,22/40)与靶向组(35.00%,14/40)比较,差异无统计学意义(P>0.05);中医组临床获益率(92.50%,37/40)高于靶向组(75.00%,30/40)(P<0.05)。治疗前,2组中医症状评分比较,差异无统计学意义(P>0.05)。与治疗前比较,2组腹胀、腹痛、纳差、乏力、大便干结、大便稀溏、便血评分及总分治疗后下降,中医组低于靶向组(P<0.05)。治疗前,2组VEGF、MMP-2、IGF-1比较,差异无统计学意义(P>0.05)。与治疗前比较,2组治疗后VEGF、MMP-2、IGF-1下降,中医组低于靶向组(P<0.05)。中医组骨髓抑制、迟发型腹泻毒性反应程度低于靶向组(P<0.05),中医组胃肠道反应、周围神经毒性、肝肾损害毒性反应程度与靶向组比较,差异无统计学意义(P>0.05)。结果中医益气通络解毒联合贝伐珠单抗治疗复发转移性直肠癌可降低VEGF、MMP-2、IGF-1表达,起到增效减毒作用。
Objective To observe the clinical efficacy of method of benefiting qi and removing obstruction in collaterals and detoxication combined with bevacizumab in the treatment of relapse and metastasis rectal cancer.Methods 80 patients with relapse and metastasis rectal cancer admitted to Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from January 2019 to June 2022 were selected and divided into the targeted group and the traditional Chinese medicine(TCM)group according to random number table method,with 40 cases in each group.Both groups were treated with FOLFIRI for chemotherapy.The targeted group was treated with bevacizumab for targeted therapy,and the TCM group was treated with benefiting qi and removing obstruction in collaterals and detoxication prescription based on the treatment of the targeted group.The objective effective rate,clinical benefit rate,and toxic reaction degree of two groups were statistically analyzed.TCM symptom scores,and the levels of vascular endothelial cell growth factor(VEGF),matrix metalloproteinase-2(MMP-2)and insulin-like growth factor 1(IGF-1)were compared between two groups.Results There was no statistically significant difference in the objetive effective rates between the TCM group(55.00%,22/40)and the targeted group(35.00%,14/40)(P>0.05).The clinical benefit rate in the TCM group(92.50%,37/40)was higher than that in the targeted group(75.00%,30/40)(P<0.05).Before treatment,there was no statistically significant difference in TCM symptom scores between two groups(P>0.05).Compared with before treatment,abdominal distension,abdominal pain,poor appetite,fatigue,dry feces,loose stool,and hemafecia scores and total score of two groups were decreased after treatment,and the TCM group was lower than the targeted group(P<0.05).Before treatment,there was no statistically significant difference in the levels of VEGF,MMP-2 and IGF-1 between two groups(P>0.05).Compared with before treatment,the levels of VEGF,MMP-2 and IGF-1 decreased after treatment,and t
作者
傅湘君
王煜
马贇贇
王燕
张云
FU Xiangjun;WANG Yu;MA Yunyun;WANG Yan;ZHANG Yun(Department of Gastrointestinal Surgery,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201210,China)
出处
《长春中医药大学学报》
2024年第6期645-649,共5页
Journal of Changchun University of Chinese Medicine
基金
上海市科学技术委员会科研计划项目(19401973000)。
关键词
益气通络解毒方
贝伐珠单抗
直肠癌
复发
转移
benefiting qi and removing obstruction in collaterals and detoxication prescription
bevacizumab
rectal cancer
relapse
metastasis
